Aldeyra Therapeutics Inc
Suletud
1.62 -8.47
Ülevaade
Aktsiahinna muutus
24h
Min
1.6099999999999999
Max
1.6400000000000001
Sissetulek | -23T -3.5M |
|---|---|
Aktsiakasum | -0.06 |
Töötajad | 7 |
EBITDA | 2.4M -3.5M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +237.42% upside |
Järgmine tulemuste avaldamine | 5. aug 2026 |
|---|
Turukapital | 2.4M 100M |
|---|---|
Eelmine avamishind | 10.09 |
Eelmine sulgemishind | 1.62 |
Aldeyra Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Aldeyra Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
237.42% tõus
12 kuu keskmine prognoos
Keskmine 5.5 USD 237.42%
Kõrge 9 USD
Madal 2 USD
Põhineb 2 Wall Streeti analüütiku instrumendi Aldeyra Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
